CAR-γδ T Cell Manufacturing Protocol for Clinical Immunotherapy

Jan Kuska describes an automated process for manufacturing chimeric antigen receptor (CAR)-engineered gamma delta T cells for cancer immunotherapy. The protocol details a 374-fold expansion of Vγ9Vδ2 T cells, achieving an average yield of 6.64×10^9 cells after 14 days, with a mean transduction efficiency of 57.4%. The document was last updated on 2026-05-22.

Use Cases

• Benchmarking cell expansion protocols based on the reported 374-fold increase in Vγ9Vδ2 T cells.
• Optimizing transduction efficiency for CAR engineering based on the described lentiviral vector and MOI of 0.12.
• Assessing final cell product purity based on the composition metrics (89.83% γδ T cells, 9.82% NK cells).
• Evaluating manufacturing safety based on the reported low average vector copy number (VCN) of 1.4.

Strengths

• Specific yield metrics: average of 6.64×10^9 cells produced after 14-day culture.
• Detailed process efficiency: 4.59-log αβT cell depletion and 3.97-log B cell depletion.
• Concrete transduction outcome: mean γδ T cell transduction efficiency of 57.4%.
• Final product characterization: average composition of 89.83% γδ T cells.

Limitations

• Metadata completeness is limited; the dataset is a 29.0 KB DOCX file describing a protocol, not structured data.
• Column-level documentation is absent; field semantics must be inferred from the text.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

figshare

Collection Method

Likely contains a documented laboratory protocol for automated cell manufacturing.

Freshness

Last updated 2026-05-22 05:35:18; freshness should be verified.